Medical Oncologist
Thyroid cancer treatment
Targeted Therapy for — Thyroid Cancer
Targeted therapy for thyroid cancer is not one treatment. It is a group of medicines chosen based on the specific mutations found in your tumour, and not every thyroid cancer has one.
Medically reviewed by Dr. T. Raghavender Reddy, Medical Oncologist, MBBS · DM (Medical Oncology) · MD (Radiation Oncology) · Last reviewed August 2026
- Type matters first — Medullary, papillary, follicular and anaplastic thyroid cancers each have a different mutation profile and different treatment options.
- Testing decides eligibility — Molecular testing of your tumour tissue identifies whether a targeted drug is likely to help you specifically.
- Radioiodine usually comes first — For differentiated thyroid cancers, radioiodine therapy is tried before targeted drugs are considered.
- RET is the key test for medullary disease — Most medullary thyroid cancers carry a RET mutation, and RET-directed drugs are now part of NCCN standard-of-care for this type.
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
Targeted therapy for thyroid cancer depends on your cancer type and the mutations found in your tumour. NCCN guidance recommends molecular testing before treatment decisions are made. The results identify which targeted drugs, if any, are likely to help. Not every thyroid cancer has an actionable mutation.
Which thyroid cancers are treated with targeted therapy?
Thyroid cancers are not all the same disease. Papillary, follicular, medullary and anaplastic types each behave differently and respond to different treatments.
Medullary thyroid cancer is the type where targeted therapy plays the clearest role. Most cases carry a RET mutation or rearrangement, and RET-directed treatment is now part of NCCN standard-of-care.
For differentiated thyroid cancers — papillary and follicular — radioiodine therapy is the first option after surgery. Targeted therapy enters when the cancer has stopped responding to radioiodine. VEGFR-directed drugs are used in this setting for eligible patients.
Anaplastic thyroid cancer is rare and aggressive. Where a BRAF V600E mutation is present, NCCN and ESMO guidance supports a BRAF plus MEK inhibitor combination as the preferred approach.
What does the choice of targeted drug depend on?
The drug your oncologist recommends depends on three things: your thyroid cancer subtype, the specific mutation found in your tumour, and whether earlier treatments such as radioiodine have already been tried.
For RET-altered cancers, newer RET-specific inhibitors are preferred over older multi-target drugs because they are more precise and have a different side-effect profile. NCCN guidance reflects this shift.
For tumours carrying an NTRK fusion — which can occur in any thyroid cancer type — NTRK inhibitors are recommended regardless of the histology. Here the mutation matters more than the cancer label.
Testing is usually done on tissue from your original biopsy, which the pathology laboratory stores. A new procedure is not always needed.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
You do not have to work this out alone
A 45-minute consultation with a specialist who treats this every week.
Which tests decide whether targeted therapy will work for you?
- RET mutation or fusion testingThe most important test for medullary thyroid cancer. Also relevant in papillary and other histologies where a RET fusion may be present.
- BRAF V600E mutationTested in papillary and anaplastic thyroid cancers. A positive result opens specific treatment options not available otherwise.
- RAS mutations (NRAS, HRAS, KRAS)Commonly found in follicular thyroid cancer and some papillary cases. Guides both prognosis and emerging treatment choices.
- NTRK gene fusionsRare but actionable across all thyroid cancer types. A positive result means an NTRK inhibitor is an option regardless of subtype.
- Radioiodine avidity assessmentNot a mutation test, but determines whether your differentiated thyroid cancer still responds to iodine — which affects whether targeted drugs are the right next step.
- ALK rearrangementsLess common, but worth testing when comprehensive molecular profiling is done, as targeted options exist for this alteration.
What should you expect if targeted therapy is recommended?
Most thyroid cancer targeted therapies are taken as oral tablets at home, not given by infusion. You will have regular blood tests and imaging to track how the treatment is working.
Side effects depend on the drug class. VEGFR inhibitors commonly cause high blood pressure, fatigue and hand-foot skin reactions. RET-specific inhibitors tend to have a different and often more manageable profile.
Targeted therapy for thyroid cancer is generally intended to control the disease and maintain quality of life. Your oncologist will explain clearly what the treatment is expected to achieve in your situation.
Response assessment typically involves thyroid function tests, thyroglobulin levels where relevant, and imaging such as ultrasound or PET-CT, with scans coordinated through partner imaging centres.
Explore 119 more Targeted Therapy Basics, Testing & Your Cancer Type topics
Cancer-Type Specific Targeted Therapy
- CML Treatment with TKIs: Living a Normal Life Span
- Cancer of Unknown Primary: Can Molecular Testing Help?
- GIST Treatment: Why This Cancer Changed Targeted Therapy Forever
- Targeted Therapy for Bile Duct Cancer (Cholangiocarcinoma)
- Targeted Therapy for Bladder and Urothelial Cancer
- Targeted Therapy for Brain Tumours and Glioma
- Targeted Therapy for Breast Cancer: HER2, HR+ and Triple Negative
- Targeted Therapy for CLL and Lymphoma
- Targeted Therapy for Cervical and Endometrial Cancer
- Targeted Therapy for Childhood Cancers
- Targeted Therapy for Colorectal Cancer: RAS, BRAF and HER2
- Targeted Therapy for Head and Neck Cancer
- Targeted Therapy for Kidney Cancer (RCC)
- Targeted Therapy for Liver Cancer (HCC)
- Targeted Therapy for Lung Cancer: Every Mutation and Drug Explained
- Targeted Therapy for Melanoma: BRAF and MEK Inhibitors
- Targeted Therapy for Multiple Myeloma
- Targeted Therapy for Neuroendocrine Tumours
- Targeted Therapy for Ovarian Cancer: PARP Inhibitors and Beyond
- Targeted Therapy for Pancreatic Cancer: Limited but Real Options
- Targeted Therapy for Prostate Cancer
- Targeted Therapy for Sarcoma
- Targeted Therapy for Stomach and Gastroesophageal Cancer
- Targeted Therapy for Thyroid Cancer
- Targeted Therapy in AML: Beyond Standard Chemotherapy
- Tumour-Agnostic Drugs: When the Mutation Matters More Than the Organ
Before You Start - Preparation & Baseline
- 25 Questions to Ask Your Oncologist Before Starting Targeted Therapy
- Before You Start Targeted Therapy: The Complete Preparation Checklist
- Dental Check-Up Before Cancer Treatment: Why It Matters
- Financial Planning Before Starting Long-Term Targeted Therapy
- How Long After Surgery Can You Start Targeted Therapy?
- How to Store Your Targeted Therapy Tablets Correctly
- Setting Up a Dosing Routine You Won't Forget
- Should Targeted Therapy Be Taken With Food or on an Empty Stomach?
- Vaccinations Before and During Cancer Treatment
- What to Expect in Your First Month on Targeted Therapy
- Which Baseline Tests Are Done Before Starting a TKI?
- Which of Your Existing Medicines Must Stop Before Targeted Therapy
- Why You Need an ECHO and ECG Before Certain Cancer Drugs
Biomarker & Molecular Testing
- Can Mutation Testing Be Done on an Old Biopsy Block or Slides?
- Cost of NGS and Mutation Testing in India: 2026 Price Guide
- Do I Need Genetic Testing Before Starting Targeted Therapy?
- Germline vs Somatic Testing: The Difference Nobody Explains Properly
- Getting a Second Opinion on Your Genomic Report
- How Long Do Mutation Test Results Take in India? Realistic Timelines
- How to Read Your Molecular Pathology Report, Line by Line
- IHC, FISH, PCR or NGS: Which Mutation Test Is Right for Your Cancer?
- Is Mutation Testing Worth It If I Can't Afford the Drug?
- Liquid Biopsy vs Tissue Biopsy: Which Test Do You Need?
- My Report Says a Mutation Is 'Actionable': What Does That Mean?
- No Mutation Found in My Report: What Are My Options Now?
- Should I Start Chemotherapy While Waiting for Mutation Results?
- Should You Repeat Molecular Testing After Your Cancer Progresses?
- Single-Gene Test or Full Panel? How to Choose Without Wasting Money
- What Are PD-L1, TMB and MSI, and Do They Affect Targeted Therapy?
- What Does 'Variant of Uncertain Significance' (VUS) Mean?
- What Happens If There Isn't Enough Tissue for Mutation Testing?
- What Is NGS (Next-Generation Sequencing) Testing in Cancer?
- What Is a Molecular Tumour Board and Why Should You Want One?
- Which Cancers Should Always Be Tested for Mutations? A Checklist
- ctDNA and MRD Testing: Tracking Cancer Through a Blood Test
Foundations & How Targeted Therapy Works
- Adjuvant and Neoadjuvant Targeted Therapy: Treatment Before or After Surgery
- Antibody-Drug Conjugates (ADCs): The Smart Bombs of Cancer Treatment
- Biosimilars and Generic Targeted Therapy Drugs: What They Are
- Can Targeted Therapy Be Combined with Chemotherapy or Radiation?
- Can Targeted Therapy Cure Cancer? An Honest Answer
- First-Line, Second-Line and Beyond: How Treatment Lines Work
- How Doctors Decide Between Chemo, Immunotherapy and Targeted Therapy
- How Does Targeted Therapy Actually Work? Explained Without Jargon
- How Long Does Targeted Therapy Take to Start Working?
- Is Targeted Therapy Painful? What the Treatment Actually Feels Like
- Is Targeted Therapy a Type of Chemotherapy? Clearing Up the Confusion
- Oral Tablets vs IV Infusion Targeted Therapy: What's the Difference?
- Precision Oncology vs Personalised Medicine: Are They the Same Thing?
- Targeted Therapy Success Rates: What the Numbers Really Mean
- Targeted Therapy for Stage 4 Cancer: What You Can Realistically Expect
- Targeted Therapy vs Chemotherapy: 12 Differences That Actually Matter
- Targeted Therapy vs Immunotherapy: Which One Is Right for You?
- The 8 Main Types of Targeted Therapy Drugs (With Examples)
- What Do Cancer Drug Endings Like -nib, -mab and -tinib Mean?
- What Is Targeted Therapy for Cancer? A Complete Patient Guide
- Which Cancers Can Be Treated with Targeted Therapy? Full List
- Why Didn't My Doctor Recommend Targeted Therapy for Me?
Mutation & Target-Specific Pages
- ALK-Positive Lung Cancer: Drugs, Response and What Comes Next
- Antiangiogenic Drugs (VEGF Inhibitors): How Starving a Tumour Works
- BCR-ABL and the Philadelphia Chromosome in CML
- BRAF V600E Mutation: Targeted Therapy Across Multiple Cancers
- BRCA vs HRD Testing: Which One Determines PARP Inhibitor Eligibility?
- BRCA1 and BRCA2 Mutations in Cancer Treatment: PARP Inhibitors
- BTK Inhibitors in CLL and Lymphoma
- CD20, CD38 and Other Antibody Targets in Blood Cancers
- CDK4/6 Inhibitors in Hormone-Positive Breast Cancer
- Co-Mutations: When You Have Two Mutations at Once
- EGFR Exon 20 Insertion: Why It's Different and Harder to Treat
- EGFR Mutation in Lung Cancer: Complete Patient Guide
- ESR1 Mutation: Why Your Hormone Therapy Stopped Working
- FGFR Alterations in Bladder and Bile Duct Cancer
- FLT3 Mutation in AML: What It Means for Your Prognosis
- HER2 Mutation in Lung and Gastric Cancer
- HER2-Low Breast Cancer: A New Category That Changes Treatment
- HER2-Positive Breast Cancer: The Full Targeted Therapy Roadmap
- IDH1 and IDH2 Mutations in Glioma, AML and Bile Duct Cancer
- KIT and PDGFRA Mutations in GIST
- KRAS G12C Mutation: The Target That Was Undruggable for 40 Years
- KRAS Mutation but Not G12C: What Are My Options?
- MET Exon 14 Skipping and MET Amplification Explained
- MSI-High and Mismatch Repair Deficiency: Testing and Treatment
- NRG1, MET, RET and Other Rare Fusions: Where to Get Tested
- NTRK Fusion: One Drug for Many Different Cancers
- Osimertinib: What to Expect, Side Effects and How Long It Works
- PALB2, ATM and Other BRCA-Like Genes: Do They Get the Same Drugs?
- PIK3CA Mutation in Breast Cancer: Alpelisib and What to Expect
- PSMA and AR-Targeted Therapy in Prostate Cancer
- RET Fusion Cancer: Lung, Thyroid and Beyond
- ROS1-Positive Cancer: A Rare Mutation with Excellent Options
- TP53 Mutation: Why There's Still No Targeted Drug for It
- Understanding Variant Allele Frequency (VAF) in Your Report
- What If My Mutation Has No Approved Drug Yet?
- mTOR Inhibitors in Cancer: Everolimus and Temsirolimus
Next step
Still not sure what applies to you?
Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.
Common questions
Frequently asked questions
Does targeted therapy work for papillary thyroid cancer?
Most papillary thyroid cancers are managed well with surgery and radioiodine, and targeted therapy is not the first step. It becomes relevant when the cancer has become radioiodine-refractory — meaning it no longer takes up iodine. In that setting, NCCN and ESMO guidance supports VEGFR-directed treatment. A proportion of papillary TC cases also carry a BRAF V600E mutation or a RET fusion, and those results may open additional targeted options. Your oncologist will advise whether testing is indicated based on how your cancer has behaved.
Do I need a new biopsy to test for mutations?
Usually not. Molecular testing is performed on the tissue from your original biopsy, which the pathology laboratory stores as a paraffin block. If the sample is too small or too degraded to give a reliable result, your team may ask for a repeat biopsy. Ask before assuming a new procedure is needed — in most cases the stored tissue is sufficient for the key tests your oncologist wants to order.
What is the difference between older and newer drugs for medullary thyroid cancer?
Older drugs used for medullary thyroid cancer targeted RET alongside several other molecular pathways. That broad action produced side effects from the off-target activity as well as from RET inhibition. Newer RET-specific drugs are designed to be more precise. NCCN guidance now prefers RET-specific inhibitors for RET-mutant or RET-fusion medullary thyroid cancer because of this more focused profile. Ask your oncologist which approach they are recommending and why the choice fits your situation.
Can targeted therapy and radioiodine be given at the same time?
Generally no. Targeted therapy for differentiated thyroid cancer is considered after radioiodine has been tried and the cancer has stopped responding — not alongside it. Giving both together is not the standard approach and is not supported by NCCN or ESMO guidance outside a clinical trial. If a combination is being recommended, ask your oncologist to explain the specific reasoning for your situation before agreeing.
Will I need to take targeted therapy tablets for the rest of my life?
The duration depends on how your cancer responds and how well you tolerate the treatment. Targeted therapy for thyroid cancer is usually continued for as long as it is working and tolerable, rather than for a fixed number of cycles. Treatment may be paused or the dose adjusted if side effects become difficult to manage. Your oncologist will review the benefit against the burden at every assessment, and that is a conversation you should be part of.
Is targeted therapy for thyroid cancer available in India, and is it expensive?
The drugs used for thyroid cancer targeted therapy are available in India, though access and cost vary. Some are available through government schemes and hospital formularies; others are priced as specialty medicines and may need insurance approval or a patient assistance programme. Any cost figure is indicative — prices change and depend on the specific drug and treatment duration. Ask your oncologist's team what your insurer covers and whether financial assistance applies to the treatment being recommended.